Dostarlimab monotherapy produced a 27% response rate in PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
|Videos|December 7, 2019
Dr. Biran on 2-Year Update of Immunotherapy Triplet in High-Risk Multiple Myeloma
Author(s)Noa Biran, MD
Noa Biran, MD, physician, John Theurer Cancer Center, discusses the 2-year update of a phase II trial of pembrolizumab (Keytruda), lenalidomide (Revlimid), and dexamethasone as post-autologous stem cell transplant consolidation in patients with high-risk multiple myeloma.
Advertisement
Noa Biran, MD, physician, John Theurer Cancer Center, discusses the 2-year update of a phase II trial of pembrolizumab (Keytruda), lenalidomide (Revlimid), and dexamethasone as post-autologous stem cell transplant consolidation in patients with high-risk multiple myeloma.
Advertisement
Related to this article
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Adam D. Cohen, MD, overviews phase 1 findings for cevostamab and outlines future research directions for the agent in relapsed/refractory multiple myeloma.
Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.
A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.
Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.
Two decades of biomarker-driven progress have reshaped lung cancer management, but late diagnosis, unequal treatment access, and underfunding remain
Phase 3 data support EGFR and ALK inhibitors as adjuvant standards of care in resectable NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
2
The OncFive: Top Oncology Articles for the Week of 8/2
3
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
4
Exploring the Rationale for 5-Alpha Reductase Inhibitors in Prostate Cancer Prevention and Active Surveillance
5